QSAM
QSAM Biosciences, Inc.
Save
36.68M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc.
Similar securities
Based on sector and market capitalization
Report issue